Circulating Tumor DNA-based Minimal Residual Disease Detection in Colorectal Cancer Management : Episode 11
ctDNA Testing in a CRC Clinical Scenario
The panel examines a clinical scenario, detailing their approach to circulating tumor DNA testing, including turnaround times, and providing insights on patient counseling.
- Would you offer ctDNA testing?
- What is the turnaround time you would expect in this case for tumor-informed assay?
- What would your treatment recommendation be in the absence of ctDNA results?
- Treatment slide questions:
- How would you counsel the patient?
- What change, if any, would you make to the treatment regimen?
Recent Videos
Related Content
FDA Approves Encorafenib/Cetuximab Plus mFOLFOX6 for Advanced BRAF V600E+ CRC
December 20th 2024Article
The FDA has granted accelerated approval to encorafenib in combination with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test.
